STOCK TITAN

BioScience Health Innovations posts $565K 9-month loss

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

BioScience Health Innovations, Inc. (BHIC) reported nine-month revenue of $2,757,381 and a net loss of $564,885 through September 30, 2026, compared with revenue of $4,115,960 and net income of $875,720 in 2025. Operating cash flow was negative $1,244,807, versus positive $272,874; cash was $1,691,858 at September 30, 2026. Third-quarter revenue was $970,071 and net loss was $149,225.

During the nine months, BHIC issued 1,048,159 common shares for $2,010,267 in cash proceeds. After quarter-end, it entered a definitive agreement to acquire 100% of Vital Core and agreed to acquire a 40% interest in a customer relationship platform from related party Ageless Holdings for 450,000 restricted shares. Rule Imports committed $250,000 in research and product-development funding to Vital Core in two equal installments and was appointed a preferred, non-exclusive master distributor for covered product lines.

Management concluded disclosure controls and internal control over financial reporting were ineffective as of September 30, 2026, identifying four material weaknesses. It plans to establish written controls and hire additional accounting staff when sufficient capital is raised.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 5 points

How the balance works

Positive

  • None.

Negative

  • Major pointManagement identified four material weaknesses and ineffective financial-reporting controls.
  • Moderate pointNine-month revenue fell to $2,757,381 from $4,115,960 in 2025.
  • Moderate pointNine-month results shifted from $875,720 net income in 2025 to a $564,885 net loss.
  • Moderate pointOperating cash flow was negative $1,244,807, versus $272,874 provided in 2025.
  • Minor pointBank balances were $1,177,674 above the stated $250,000 FDIC insurance limit.

Filing Explained

Only the platform-interest agreement calls for additional common shares; the separate Vital Core acquisition requires none.

The filing shows the agreed 450,000-share consideration for the 40% platform interest as a pro forma adjustment: common shares were 12,027,217 on November 12, 2026 and are shown as 12,477,217 pro forma; the Vital Core acquisition requires no additional common shares. If issued, the platform shares would increase the share count and reduce existing holders’ percentage ownership, absent offsetting changes.

The company’s approximately $2,025,000 reference value for the platform interest is based on its $4.50 Regulation A offering price; the filing says this is not the acquisition-date fair value for financial reporting.

As of September 30, 2026, 140,000 Series A preferred shares were outstanding, each convertible at the holder’s election into three common shares, or 420,000 in total; the filing excludes these potential shares from diluted loss per share as antidilutive. If converted, they would increase the common share count and reduce existing holders’ percentage ownership, absent offsetting changes.

Revenue $2,757,381 Nine months ended September 30, 2026; $4,115,960 in the same 2025 period.
Net income (loss) ($564,885) Nine months ended September 30, 2026; net income of $875,720 in the same 2025 period.
Operating cash flow ($1,244,807) Nine months ended September 30, 2026; $272,874 provided in the same 2025 period.
Cash $1,691,858 As of September 30, 2026.
Common shares issued for cash 1,048,159 shares; $2,010,267 proceeds Nine months ended September 30, 2026.
Material weaknesses 4 Management identified four material weaknesses in internal control over financial reporting as of September 30, 2026.
Platform interest consideration 40% interest; 450,000 restricted shares Agreed November 5, 2026 with related party Ageless Holdings.
Research funding commitment $250,000 Committed by Rule Imports to Vital Core on November 6, 2026, payable in two equal installments.
MODS Max technical
"MODS Max is described in Company technical materials"
beneficial ownership limitation regulatory
"subject to a 4.99% beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
deferred revenue financial
"payment received by the Company prior to product delivery is recorded as deferred revenue"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
antidilutive financial
"because they were antidilutive"
Describes a potential common share — such as a convertible bond, convertible preferred, option or warrant — that would, if included in the diluted earnings-per-share calculation, increase (or fail to decrease) reported earnings per share rather than dilute it. Accounting rules require such securities to be excluded from diluted EPS because their assumed conversion would make EPS higher (or make a loss per share smaller), so they are not treated as dilutive when reporting diluted figures.
material weaknesses financial
"The material weaknesses identified during management’s assessment"
Material weaknesses are significant flaws in a company’s systems for ensuring its financial reports are accurate and reliable. Like a broken lock on a safe, they increase the chance that financial statements contain big errors or omissions, which can mislead investors about performance and risk; discovering one often raises questions about management oversight, may lead to restated results, and can affect investor confidence and a company’s valuation.
fair value model financial
"based on the fair value model under ASU 2023-08"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did BHIC report for the first nine months of 2026?

BHIC reported $2,757,381 in revenue for the nine months ended September 30, 2026, compared with $4,115,960 in the same period of 2025. The company reported a net loss of $564,885 for the 2026 period.

What did BHIC agree to acquire after September 2026?

On November 5, 2026, BHIC entered a definitive agreement to acquire 100% of Vital Core, Inc. Separately, it agreed to acquire a 40% interest in a customer relationship platform from Ageless Holdings for 450,000 restricted shares. The platform’s customer base consists of approximately 15,000 active peptide, health, and wellness customers; the stated $2,025,000 reference value is not its acquisition-date fair value.

What are the terms of BHIC’s Rule Imports research-funding agreement?

On November 6, 2026, Rule Imports committed to provide $250,000 in research and product-development funding to Vital Core in two equal installments of $125,000. Vital Core also appointed Rule Imports a preferred, non-exclusive master distributor for covered product lines.

What control weaknesses did BHIC report?

Management concluded controls were ineffective as of September 30, 2026, citing insufficient internal accounting resources, lack of segregation of duties, lack of an independent board or audit committee, and lack of written internal-control policies and procedures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001784440 --12-31 false true 2026 Q3 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0001784440 2026-01-01 2026-09-30 0001784440 2026-09-30 0001784440 2026-11-12 0001784440 2026-09-30 2026-09-30 0001784440 2025-12-31 2025-12-31 0001784440 2025-12-31 0001784440 2026-07-01 2026-09-30 0001784440 2025-07-01 2025-09-30 0001784440 2025-01-01 2025-09-30 0001784440 2024-12-31 0001784440 us-gaap:PreferredStockMember 2024-12-31 0001784440 us-gaap:CommonStockMember 2024-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001784440 us-gaap:RetainedEarningsMember 2024-12-31 0001784440 2025-01-01 2025-03-31 0001784440 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001784440 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001784440 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001784440 2025-03-31 0001784440 us-gaap:PreferredStockMember 2025-03-31 0001784440 us-gaap:CommonStockMember 2025-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001784440 us-gaap:RetainedEarningsMember 2025-03-31 0001784440 2025-04-01 2025-06-30 0001784440 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001784440 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001784440 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001784440 2025-06-30 0001784440 us-gaap:PreferredStockMember 2025-06-30 0001784440 us-gaap:CommonStockMember 2025-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001784440 us-gaap:RetainedEarningsMember 2025-06-30 0001784440 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001784440 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001784440 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001784440 2025-09-30 0001784440 us-gaap:PreferredStockMember 2025-09-30 0001784440 us-gaap:CommonStockMember 2025-09-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001784440 us-gaap:RetainedEarningsMember 2025-09-30 0001784440 us-gaap:PreferredStockMember 2025-12-31 0001784440 us-gaap:CommonStockMember 2025-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001784440 us-gaap:RetainedEarningsMember 2025-12-31 0001784440 2026-01-01 2026-03-31 0001784440 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001784440 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001784440 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001784440 2026-03-31 0001784440 us-gaap:PreferredStockMember 2026-03-31 0001784440 us-gaap:CommonStockMember 2026-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001784440 us-gaap:RetainedEarningsMember 2026-03-31 0001784440 2026-04-01 2026-06-30 0001784440 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001784440 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001784440 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001784440 2026-06-30 0001784440 us-gaap:PreferredStockMember 2026-06-30 0001784440 us-gaap:CommonStockMember 2026-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001784440 us-gaap:RetainedEarningsMember 2026-06-30 0001784440 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001784440 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001784440 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001784440 us-gaap:PreferredStockMember 2026-09-30 0001784440 us-gaap:CommonStockMember 2026-09-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001784440 us-gaap:RetainedEarningsMember 2026-09-30 0001784440 2025-01-01 2025-12-31 0001784440 us-gaap:PatentsMember 2026-09-30 0001784440 us-gaap:PatentsMember 2025-12-31 0001784440 fil:ComputerSoftwareMember 2026-09-30 0001784440 fil:ComputerSoftwareMember 2025-12-31 0001784440 2025-12-01 2025-12-01 0001784440 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001784440 fil:RelatedParty1Member 2025-09-30 0001784440 fil:RelatedParty1Member 2025-01-01 2025-09-30 0001784440 fil:RelatedParty1Member 2026-09-30 0001784440 fil:RelatedParty1Member 2026-01-01 2026-09-30 0001784440 fil:RelatedParty1Member 2026-01-01 2026-03-31 0001784440 fil:RelatedParty1Member 2026-03-31 0001784440 2025-09-09 0001784440 2025-09-10 2025-09-10 0001784440 2025-09-10 0001784440 us-gaap:PreferredStockMember 2021-10-19 0001784440 us-gaap:SeriesAPreferredStockMember 2021-11-01 0001784440 us-gaap:SeriesAPreferredStockMember 2021-11-01 2021-11-01 0001784440 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001784440 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001784440 fil:UsdtMember 2026-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

 

Mark One

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                             to                          

 

Commission File No. 333-234487

 

BIOSCIENCE HEALTH INNOVATIONS INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

7374

 

98-1498782

(State or Other Jurisdiction of

 

(Primary Standard Industrial

 

(IRS Employer

Incorporation or Organization)

 

Classification Number)

 

Identification Number)

 

14857 South Concord Park Drive

Bluffdale, UT 84065

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (801) 949-0791

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

None

 

None

 

None

 

Securities registered pursuant to Section 12(g) of the Act: Common stock, par value $0.0001

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated Filer ☐

Non-accelerated filer ☒

Smaller reporting company ☒

Emerging growth company ☒

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the practicable date:

 

Class

 

Outstanding as of

November 12, 2026

Common Stock: $0.0001 par value

 

12,027,217

 


 

TABLE OF CONTENTS

 

PART 1 FINANCIAL INFORMATION

 

 

Item 1.

 

Financial Statements

 

3

 

 

Condensed Consolidated Balance Sheets (unaudited)

 

4

 

 

Condensed Consolidated Statements of Operations (unaudited)

 

5

 

 

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (unaudited)

 

6

 

 

Condensed Consolidated Statements of Cash Flows (unaudited)

 

7

 

 

Notes to Financial Consolidated Statements (unaudited)

 

8

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

14

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

21

Item 4.

 

Controls and Procedures

 

21

 

 

 

 

 

PART II OTHER INFORMATION

 

 

Item 1.

 

Legal Proceedings

 

22

Item 1A.

 

Cybersecurity

 

22

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

22

Item 3.

 

Defaults Upon Senior Securities

 

22

Item 4.

 

Mine Safety Disclosures

 

22

Item 5.

 

Other Information

 

22

Item 6.

 

Exhibits

 

23

 

 

Signatures

 

24


Table of Contents

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. These financial statements should be read in conjunction with the Company’s December 31, 2025 audited financial statements and notes thereto. Operating results for the nine months ended September 30, 2026 are not necessarily indicative of the results that can be expected for the year ending December 31, 2026.


3


 

Table of Contents

 

BIOSCIENCE HEALTH INNOVATIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

September 30,

 

December 31,

2026

 

2025

 

(Unaudited)

 

 

ASSETS

 

 

 

Current Assets

 

 

 

Cash and cash equivalents

$1,691,858  

 

$661,925 

Accounts receivable, net

478,083  

 

399,257 

Income tax receivable

34,992  

 

- 

Operating digital assets

71  

 

- 

Inventory

711,269  

 

336,348 

Prepaid expense

91,378  

 

21,341 

Overpayment to related parties

-  

 

137,718 

Deferred tax asset

-  

 

2,069 

Total current assets

3,007,651  

 

1,558,658 

Other Assets

 

 

 

Intangible assets

170,307  

 

82,887 

Deposits

4,400  

 

4,400 

Right -of-use asset

21,870  

 

61,236 

Total other assets

196,577  

 

148,523 

 

 

 

 

Total Assets

$3,204,228  

 

$1,707,181 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

Current Liabilities

 

 

 

Accounts payable

$38,653  

 

$6,274 

Accrued expenses

26,201  

 

7,957 

Income tax payable

-  

 

79,030 

Deferred revenue

1,522  

 

136,590 

Related party advances

8,803  

 

- 

Insurance loan

25,935  

 

- 

Note payable - related party

180,402  

 

- 

Total current liabilities

281,516  

 

229,851 

 

 

 

 

STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

Preferred stock: $0.0001 par value, 5,000,000 shares authorized;

-  

 

- 

Series A Convertible Preferred Stock, 1,000,000 designated,
140,000 shares issued and outstanding at September 30, 2026 and December 31, 2025

14  

 

14 

Common stock: $0.0001 par value, 250,000,000 shares authorized; 12,027,217 and
  10,979,058 shares issued and outstanding at September 30, 2026 and December 31, 2025

1,203  

 

1,098 

Additional paid-in capital

3,185,373  

 

1,175,211 

Accumulated earnings (deficit)

(263,878) 

 

301,007 

Total stockholders' equity (deficit)

2,922,712  

 

1,477,330 

Total Liabilities and Stockholders' Equity (Deficit)

$3,204,228  

 

$1,707,181 

 

See accompanying notes to the unaudited condensed consolidated financial statements.


4


 

Table of Contents

 

BIOSCIENCE HEALTH INNOVATIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

For the Three Months Ended

 

For the Nine Months Ended

 

 

September 30,

 

September 30,

 

2026

 

2025

 

2026

 

2025

 

 

 

 

 

 

 

 

 

Revenues

 

$970,071  

 

$1,131,427  

 

$2,757,381  

 

$4,115,960  

Cost of goods sold

 

(332,507) 

 

(433,196) 

 

(974,738) 

 

(1,447,106) 

Gross Profit

 

637,564  

 

698,231  

 

1,782,643  

 

2,668,854  

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

General and administrative expenses

 

720,121  

 

576,656  

 

2,150,066  

 

1,550,291  

Consulting fees

 

65,703  

 

130,357  

 

228,626  

 

242,843  

Total Operating Expenses

 

785,824  

 

707,013  

 

2,378,692  

 

1,793,134  

 

 

 

 

 

 

 

 

 

Income (Loss) from Operations

 

(148,260) 

 

(8,782) 

 

(596,049) 

 

875,720  

 

 

 

 

 

 

 

 

 

Other Expense:

 

 

 

 

 

 

 

 

Interest expense

 

965  

 

-  

 

965  

 

-  

Total Other Expense

 

965  

 

-  

 

965  

 

-  

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

(149,225) 

 

(8,782) 

 

(597,014) 

 

875,720  

Income tax expense

 

-  

 

-  

 

(32,129) 

 

-  

 

 

 

 

 

 

 

 

 

Net Income (Loss)

 

$(149,225) 

 

$(8,782) 

 

$(564,885) 

 

$875,720  

 

 

 

 

 

 

 

 

 

Net income (loss) per common share - basic

 

$(0.01) 

 

$(0.00) 

 

$(0.05) 

 

$0.08  

Net income (loss) per common share - diluted

 

$(0.01) 

 

$(0.00) 

 

$(0.05) 

 

$0.08  

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding – basic

 

11,838,175  

 

10,979,058  

 

11,516,638  

 

10,979,058  

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding – diluted

 

11,838,175  

 

10,979,058  

 

11,516,638  

 

11,399,058  

 

See accompanying notes to the unaudited condensed consolidated financial statements.


5


Table of Contents

 

BIOSCIENCE HEALTH INNOVATIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(Unaudited)

 

 

Series A Convertible

 

 

 

 

 

Additional

 

 

 

 

 

Preferred Stock

 

Common Stock

 

Paid-in

 

Accumulated

 

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Earnings (Deficit)

 

Total

Balance at December 31, 2024

140,000 

 

$14 

 

10,979,058 

 

$1,098 

 

$1,175,211 

 

$(341,083) 

 

$835,240  

Net income

- 

 

- 

 

- 

 

- 

 

- 

 

426,798  

 

426,798  

Balance at March 31, 2025

140,000 

 

14 

 

10,979,058 

 

1,098 

 

1,175,211 

 

85,715  

 

1,262,038  

Net income

- 

 

- 

 

- 

 

- 

 

- 

 

457,704  

 

457,704  

Balance at June 30, 2025

140,000 

 

14 

 

10,979,058 

 

1,098 

 

1,175,211 

 

543,419  

 

1,719,742  

Net loss

- 

 

- 

 

- 

 

- 

 

- 

 

(8,782) 

 

(8,782) 

Balance at September 30, 2025

140,000 

 

$14 

 

10,979,058 

 

$1,098 

 

$1,175,211 

 

$534,637  

 

$1,710,960  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2025

140,000 

 

$14 

 

10,979,058 

 

$1,098 

 

$1,175,211 

 

$301,007  

 

$1,477,330  

Common shares issued for cash

- 

 

- 

 

437,067 

 

44 

 

437,023 

 

-  

 

437,067  

Net loss

- 

 

- 

 

- 

 

- 

 

- 

 

(229,907) 

 

(229,907) 

Balance at March 31, 2026

140,000 

 

14 

 

11,416,125 

 

1,142 

 

1,612,234 

 

71,100  

 

1,684,490  

Common shares issued for cash

- 

 

- 

 

336,204 

 

34 

 

336,170 

 

-  

 

336,204  

Net loss

- 

 

- 

 

- 

 

- 

 

- 

 

(185,753) 

 

(185,753) 

Balance at June 30, 2026

140,000 

 

14 

 

11,752,329 

 

1,176 

 

1,948,404 

 

(114,653) 

 

1,834,941  

Common shares issued for cash

- 

 

- 

 

274,888 

 

27 

 

1,236,969 

 

-  

 

1,236,996  

Net loss

- 

 

- 

 

- 

 

- 

 

- 

 

(149,225) 

 

(149,225) 

Balance at September 30, 2026

140,000 

 

$14 

 

12,027,217 

 

$1,203 

 

$3,185,373 

 

$(263,878) 

 

$2,922,712  

 

See accompanying notes to the unaudited condensed consolidated financial statements.


6


Table of Contents

 

BIOSCIENCE HEALTH INNOVATIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

For the Nine Months Ended

 

September 30,

 

2026

 

2025

   

 

 

 

Cash Flows From Operating Activities

 

 

 

Net Income (Loss)  

$(564,885) 

 

$875,720  

Adjustments to reconcile net loss to net cash used in

 

 

 

operating activities  

 

 

 

Lease cost, net of repayments  

39,366  

 

-  

Operating expenses paid with digital assets

19  

 

-  

Changes in operating assets and liabilities:

 

 

 

Accounts receivable  

(78,826) 

 

37,073  

Income tax receivable  

(34,992) 

 

-  

Inventory  

(328,781) 

 

(699,181) 

Digital assets

(46,230) 

 

-  

Deferred revenue  

(135,068) 

 

86,662  

Deferred tax

2,069  

 

-  

Accrued interest

965  

 

-  

Accrued expenses  

18,244  

 

693  

Accounts payable

32,379  

 

1,939  

Income tax payable  

(79,030) 

 

-  

Prepaid expenses  

(70,037) 

 

(30,032) 

Net Cash Provided by (Used in) Operating Activities

(1,244,807) 

 

272,874  

 

 

 

 

Cash Flows From Investing Activities

 

 

 

Purchase of intangible assets  

(87,420) 

 

(46,064) 

Net Cash Used in Investing Activities

(87,420) 

 

(46,064) 

 

 

 

 

Cash Flows From Financing Activities

 

 

 

Advances from related parties

756,923  

 

2,422,096  

Repayment of related party advances

(150,000) 

 

(2,172,000) 

Repayment of related party note payable

(280,000) 

 

-  

Advanced from insurance loan

42,663  

 

-  

Repayments to insurance loan

(17,693) 

 

-  

Proceeds from the sale of common stock

2,010,267  

 

-  

Net Cash Provided by Financing Activities

2,362,160  

 

250,096  

   

 

 

 

Net Increase in Cash

1,029,933  

 

476,906  

Cash at Beginning of Period

661,925  

 

662,517  

Cash at End of Period

$1,691,858  

 

$1,139,423  

   

 

 

 

Supplemental Cash Flow Information:

 

 

 

Cash paid for interest

$-  

 

$-  

Cash paid for income taxes

$-  

 

$-  

 

 

 

Conversion of related party advances to related party note payable

$460,402  

 

$-  

Purchase of inventory with digital assets

$46,140  

 

$-  

 

See accompanying notes to the unaudited condensed consolidated financial statements.


7


Table of Contents

 

BIOSCIENCE HEALTH INNOVATIONS INC (FORMALY KNOWN AS NOWTRANSIT INC.)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

(Unaudited)

 

Note 1 - Nature of Organization

 

Nowtransit Inc. (the “Company,” “us,” “we,” “Nowtransit”) was incorporated in the State of Nevada on July 8, 2019, and changed its name to BioScience Health Innovations Inc on February 21, 2025. Through March 10, 2023 we had no operations and had not generated any material revenues since inception. Effective March 10, 2023, we closed on a Share Exchange Agreement with Best 365 Labs Inc. (“Best”), a Nevada corporation, wherein we acquired all of the shares of Best and Best became a wholly owned subsidiary of the Company.

 

Best was incorporated on October 12, 2021 in the State of Nevada. Best sells clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels in the health and wellness market.

 

Note 2 - Liquidity

 

The condensed consolidated financial statements have been prepared in accordance with US generally accepted accounting principles, which assumes that the Company’s management will evaluate whether it will be able to meet its obligations and continue its operations in the normal course of business.

 

The Company had net income of $642,090 and positive cash provided by operating activities of $172,178 for the year ended December 31, 2025. While the Company had a net loss of $564,885 during the nine months ended September 30, 2026, they recorded accumulated deficit of $263,878, had net working capital of $2,726,135, and reported cash of $1,691,858 as of September 30, 2026, which management believes is sufficient to meet its obligations over the next year. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company determine it shall be unable to continue as a going concern.

 

Note 3 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and with the rules and regulations of the Securities and Exchange Commission, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements and should be read in conjunction with our audited financial statements. The financial statements are presented in US dollars, and the Company has adopted a December 31 year end.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates.

 

Segment Reporting

 

The Company operates as a single operating and reportable segment as a retailer selling mental health and general wellness products. Our Chief Executive Officer, who serves as our Chief Operating Decision Maker (“CODM”), evaluates the Company’s financial performance and makes resource allocation decisions considering our one geographical area and on a consolidated basis. Accordingly, the CODM considers the revenue, operating expenses, and other income (expenses) of our single operating segment as reported on the statement of operations and considers our current and total assets as recorded on the balance sheet. There are no additional expense or asset information that are supplemental to those disclosed in these condensed consolidated financial statements that are regularly provided to the CODM.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash on hand, cash in banks and any highly liquid investments with a maturity of three months or less to the extent the funds are not being held for investment purposes. As of September 30, 2026 and December 31, 2025, the Company had no cash equivalents.

 

The Company maintains four accounts at Wells Fargo Bank. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. As of September 30, 2026 the Company has balances of $1,177,674 more than this limit.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company records an allowance for doubtful accounts that is based on historical trends, customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management’s estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to collect a receivable have failed. As of September 30, 2026 and December 31, 2025, the allowance for doubtful accounts was $0.


8


 

Table of Contents

 

Inventory

 

The Company’s inventory is recognized in accordance with Accounting Standards Codification (“ASC”) 303. The Company uses the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of September 30, 2026 and December 31, 2025, the Company had $274,443 and $336,348 of finished goods on hand, respectively. And on September 30, 2026 and December 31, 2025, the Company had $436,826 and $0 of raw materials on hand respectively.

 

Income Taxes

 

The provision for income taxes and deferred income taxes is determined using the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered, a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected to be realized.

 

Revenue Recognition

 

The Company’s revenue is recognized in accordance with Accounting Standards Codification 606 and the Company sells products in the immune health supplement market. The Company’s performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers that are end users of the Company’s products will generally remit payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred revenue. Customers that are resellers of the Company’s products are offered credit terms and generally pay within 30-60 days. As of September 30, 2026 and December 31, 2025 deferred revenue was $1,522 and $136,590, respectively. Shipping and handling costs that occur are paid by the customer and is not recorded as revenue. The Company has a policy to provide a refund on any product returned by the customer and refunds are recorded as a reduction in revenue. Refunds have been minimal to date.

 

Advertising Costs

 

Advertising costs are expensed as incurred. During the nine months ended September 30, 2026 and 2025, the Company incurred advertising costs of $442,662 and $272,373, respectively.

 

Research and Development

 

The Company charges research and development costs to expense when incurred. During the nine months ended September 30, 2026 and 2025, the Company incurred $179,847 and $66,372 in research and development expenses, respectively.

 

Intangible Assets

 

The Company accounts for its intangible assets in accordance with ASC 350. Costs incurred to renew or extend the term of intangible assets are expensed as incurred.

 

 

 

Estimated Useful Life (years)

 

September 30, 2026

 

December 31, 2025

Patents

 

20

 $

117,225

$

82,887

Software

 

15

 

53,082

 

-

 

 

 

 

  170,307

 

  82,887

Accumulated amortization

 

 

 

  -

 

  -

Net book value

  

 

 $

  170,307

$

  82,887

 

During the nine months ended September 30, 2026 and 2025 no amortization expense was recorded as the patents were still pending. The patent costs will be amortized on a straight-line basis over its estimated useful life once the patents are granted. Software will begin amortization in October 2026 as the Company did not start using the software till the end of the quarter. The software is a closed loop AI system that the Company will utilize in interacting with customers and analysing Company data. Amortization expense of $885 is expected for the year ended December 31, 2026 and $9,400 for each year ended December 31, 2027 and beyond.

 

We have several patent applications pending in the U.S. and internationally for our innovative methylithioninium (methylene blue) and mitochondrial health compositions:

 

Patent Pending Product Overview and Update

 

U.S. Non-Provisional Patent Application No. 18/931,277 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024

 

International Patent Application No. PCT/US24/53487 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024

 

U.S. Non-Provisional Patent Application No. 18/931,346 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024

 

International Patent Application No. PCT/US24/53490 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024. Filed on 10/30/2024

 

U.S. Provisional Patent Application No. 19/371,824 for TREATMENTS USING METHYLTHIONINIUM SALT, LIQUID MINERAL BLENDS, and/or SECONDARY PHYSIOLOGICALLY ACTIVE COMPOUND AND PHYSIOLOGICAL THERAPY, filed on 10/28/2025


9


 

Table of Contents

 

U.S. Provisional Patent Application No. 63/712,895 for TREATMENTS USING METHYLTHIONINIUM SALT, SECONDARY PHYSIOLOGICALLY ACTIVE COMPOUND AND PHYSIOLOGICAL THERAPY, filed on 10/28/2024

 

U.S. Provisional Patent Application No. 63/754,434 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS, filed on 2/5/2025

 

U.S. Provisional Patent Application No. 19/173,875 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS, filed on 4/9/2025

 

International Patent Application No. PCT/US26/13809 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS, filed on 2/4/2026

 

U.S. Provisional Patent Application No. 64/025,742 for AQUEOUS PEPTIDE DELIVERY COMPOSITIONS AND METHODS, filed on 4/2/2026

 

All provisional applications were filed with the U.S. Patent and Trademark Office by Thorpe North and Western.

 

We believe these filings cover multiple potential patents and product opportunities. Leadership is actively exploring partnerships and strategic alliances to maximize value for stakeholders.

 

All products and methods described remain patent pending as of the date of this filing.

 

Impairment of Long-lived Assets

 

The Company applies the provisions of ASC 360, where applicable, to all long-lived assets and periodically evaluates the carrying value of long-lived assets to be held and used for impairment. Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in the results of operations. During the nine months ended September 30, 2026 and 2025, the Company recorded no impairment expense for their long-lived assets.

 

Digital Assets Held for Operational Purposes

 

The Company holds certain digital assets (primarily USDT) exclusively as a medium of exchange to facilitate inventory procurement from international vendors. Digital assets held for operational purposes are classified as current assets on the Consolidated Balance Sheets based on the Company’s intent and ability to utilize these assets within its normal operating cycle. The Company measures digital assets at fair value with changes recognized in other income (expense) in the Consolidated Statement of Operations. The Company tracks its cost basis of digital assets by-wallet in accordance with the first-in-first-out (“FIFO”) method of accounting.

 

Leases

 

The Company follows the provisions of ASC 842, and records right-of-use (“ROU”) assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company’s leases is not readily determinable, the Company’s applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments. The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option.

 

The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less.

 

On December 1, 2025, we entered a 15-month rental arrangement for our office and inventory space, at which time we paid for the lease in full with a single payment of $65,610. Because there were no future lease payments to be made, we recorded an ROU asset at lease commencement for the value of the prepayment of $65,610 and had no lease liability to record. Before December 1, 2025, the Company had a month-to-month rental agreement. The Company recorded rent expense of $39,366 and $12,915, during the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the weighted average remaining lease term was 5 months.

 

Net Income (Loss) per Common Share

 

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants. As of September 30, 2026 and 2025 there were dilutive securities of 420,000 for the conversion of Series A Convertible Preferred Stock. These potentially dilutive securities were not included in the calculation of diluted net loss per common share for the three or nine months ended September 30, 2026 because they were antidilutive.  For the three and nine months ended September 30, 2026, basic and diluted weighted average common shares outstanding and net loss per common share are the same.

 

Recent Accounting Pronouncements

 

The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements and has determined that there have been no standards that had, or will have, a material impact on its consolidated financial statements with exception to the following:


10


 

Table of Contents

 

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires incremental disclosures about specific expense categories, including but not limited to, purchases of inventory, employee compensation, depreciation, amortization and selling expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted and the amendments may be applied either prospectively or retrospectively. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. The amendments only impact disclosures and are not expected to have an impact on the Company’s financial condition and results of operations.

 

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in the absence of a principal, most advantageous market for the specific asset or liability.

 

U.S. generally accepted accounting principles provide for a three-level hierarchy of inputs to valuation techniques used to measure fair value, defined as follows:

 

 

Level 1:

Inputs that are quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity can access.

 

 

 

 

Level 2:

Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability, including:

 

 

-

quoted prices for similar assets or liabilities in active markets;

 

-

quoted prices for identical or similar assets or liabilities in markets that are not active;

 

-

inputs other than quoted prices that are observable for the asset or liability; and

 

-

inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

 

Level 3:

Inputs that are unobservable and reflect management’s own assumptions about the inputs market participants would use in pricing the asset or liability based on the best information available in the circumstances (e.g., internally derived assumptions surrounding the timing and amount of expected cash flows).

 

Our financial instruments consist of cash, accounts receivable and accounts payable, and note payable. We have determined that the book value of our outstanding financial instruments as of June 30, 2026, and December 31, 2025, approximates the fair value due to their short-term nature or interest rates that approximate prevailing market rates.

 

Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of September 30, 2026:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Operating digital assets (see Note 7)

 

$

71

 

 

$

-

 

 

$

-

 

 

$

71

 

Total Assets

 

$

71

 

 

$

-

 

 

$

-

 

 

$

71

 

Total Liabilities

 

$

-

 

 

$

-

 

 

$

-

 

 

$

-

 

 

Note 4 - Related Party Transactions

 

During the nine months ended September 30, 2025 the Company received advances of $2,422,096 from Ageless Holdings, LLC (“Holdings”), an entity owned and controlled by the Company’s members of management and board of directors, which included the purchase of $2,106,133 worth of inventory, $25,000 for services provided, and $290,693 to pay for operating expenses. The Company paid back $2,172,000 of the advances.

 

During the nine months ended September 30, 2026 the Company purchased $745,060 worth of inventory from Holdings, received $11,863 worth of advances from Holdings to pay for operating expenses, and paid back $150,000 of the advances. Additionally, during the first quarter of 2026 the Board of Directors decided to finalize a settlement agreement with Holdings and entered a promissory note on March 28, 2026 for $460,402, which was equal to the amount owed to them as of that date. The note carries an interest rate of 7% per annum, can be prepaid at any time without penalty, and matures on December 31, 2026. During the nine months ended September 30, 2025, repayments of $280,000 were made toward this note payable.

 

Note 5 – Insurance Loan

 

In May 2026 we received proceeds of $42,663 from a loan entered into to cover insurance premiums.  Under the terms of the loan interest is to accrue at a rate of 7.95% per annum and instalment payments of $4,423 monthly began in June 2026.  During the nine months ended September 30, 2026, we recorded $965 worth of interest on the loan.  During the nine months ended September 30, 2026, we made principal and interest payments on the loan of $17,693.

 

Note 6 - Equity

 

Common Stock

 

The Company has 250,000,000, $0.0001 par value shares of voting common stock authorized.

 

During the nine months ended September 30, 2026, the Company issued 1,048,159 shares in common stock for cash proceeds of $2,010,267.


11


 

Table of Contents

 

On September 10, 2025, the Company filed a change in the articles of incorporation and increased the voting common stock from 75,000,000 to 250,000,000. In addition, the Company completed a 1 for 4 reverse common stock split, decreasing the number of voting common stock outstanding from 43,916,221 to 10,979,058. All share numbers presented in these consolidated financial statements have been retroactively adjusted for the stock split.

 

During the nine months ended September 30, 2025, there were no issuances of common stock.

 

As of September 30, 2026 and December 31, 2025, the Company had 12,027,217 and 10,979,058 shares of common stock issued and outstanding, respectively.

 

Preferred Stock

 

On October 19, 2021, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing up to 5,000,000 shares of Preferred Stock, par value $0.0001 per share, with such rights, preferences and limitations as may be set forth in resolutions adopted by the Board of Directors. On November 1, 2021, the Company filed a Certificate of Designation designating 1,000,000 shares of Preferred Stock as Series A Convertible Preferred Stock (the “Series A”). Each share of the Series A is convertible into three shares of the Company’s common stock at the holder’s election, subject to a 4.99% beneficial ownership limitation which may be increased to 9.99% upon 61 days’ notice.

 

During the nine months ended September 30, 2026 and 2025 there were no issuances of preferred stock. As of September 30, 2026 and December 31, 2025, the Company had 140,000 shares of Series A Convertible Preferred Stock outstanding.

 

Note 7 – Digital Assets   

 

The Company accounts for digital assets in accordance with ASU 2023-08, which requires entities to measure crypto assets at fair value with changes recognized in the Statement of Operations each reporting period.

 

The following table presents the Company’s Digital Asset holdings as of September 30, 2026:

 

 

 

Quantity

 

Cost Basis

 

Fair Value

USDT

 

 

71

 

 

$

71

 

 

$

71

 

Total digital assets held as of September 30, 2026

 

 

 

 

 

$

71

 

 

$

71

 

 

The following table presents a roll-forward of total digital assets for the nine months ended September 30, 2026, based on the fair value model under ASU 2023-08:

 

 

 

Fair Value

Balance as of December 31, 2025

 

$

- 

 

Purchase of digital assets

 

 

46,230  

 

Operating expenses paid with digital assets

 

 

(19)

 

Purchase of inventory with digital assets

 

 

(46,140)

 

Balance as of September 30, 2026

 

$

71

 

 

Note 8 - Subsequent Events

 

The Company has evaluated all events that occur after the balance sheet date through November 13, 2026, the date when the financial statements were available to be issued, to determine if they must be reported. Management of the Company determined that there are material subsequent events to be disclosed.

 

(A)Acquisition of Vital Core and Customer Relationship Platform 

 

On November 5, 2026, the Company entered into a definitive agreement to acquire 100% of Vital Core, Inc. ("Vital Core"), which will operate as a wholly owned subsidiary of the Company upon closing. Vital Core develops hair-growth and scalp-care technologies utilizing proprietary formulations and Mods Max-enabled applications.

 

Separately, on November 5, 2026, the Company agreed to acquire a 40% ownership interest in an established customer relationship platform from Ageless Holdings, LLC ("Ageless Holdings"), a related party. The customer base consists of approximately 15,000 active peptide, health, and wellness customers. As consideration for the 40% interest, the Company agreed to issue 450,000 restricted shares of its common stock to Ageless Holdings. Solely for reference purposes based on the Company's $4.50 Regulation A offering price, the indicated transaction reference value is approximately $2,025,000; this negotiated benchmark does not represent the acquisition-date fair value to be recorded for financial reporting purposes. The Vital Core acquisition did not require the issuance of additional common shares. The related-party transaction will be documented and evaluated in accordance with the Company’s governance and SEC reporting requirements.

 

(B)Subsidiary Research Funding and Master Distribution Agreement 

 

On November 6, 2026, the Company's subsidiary, Vital Core, entered into a Research Funding and Master Distributor Agreement with Rule Imports, LLC ("Rule Imports"). Under the terms of the agreement, Rule Imports committed to provide $250,000 in research and product development funding to Vital Core, payable in two equal installments of $125,000. The funding will support product development across Vital Core, Best365Labs, and other authorized Company product lines.

 

In addition, Vital Core appointed Rule Imports as a preferred, non-exclusive master distributor for covered product lines across its established sales channels in the peptide, health, and wellness markets. Rule Imports will receive research updates and ongoing access to research findings for product evaluation and commercial distribution planning.


12


 

Table of Contents

 

The following is a pro forma consolidated balance sheet showing the balances after adjustments for the acquisition of the 40% ownership interest in the customer relationship platform and the receipt of funds from Rule Imports under Research Funding and Master Distributor Agreement.

 

BIOSCIENCE HEALTH INNOVATIONS, INC.

PRO FORMA PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEET

 

 

 

 

(A)

 

(B)

 

 

 

 

 

Acquired Customer

 

Deferred

 

Pro Forma

 

September 30,

 

Relationship

 

Research

 

Following

 

2026

 

Platform

 

Funding

 

Transactions

 

(Unaudited)

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

Cash and cash equivalents

$1,691,858  

 

 

 

 

 

$1,691,858  

Restricted Cash

 

 

 

 

$250,000 

 

250,000  

Accounts receivable, net

478,083  

 

 

 

 

 

478,083  

Income tax receivable

34,992  

 

 

 

 

 

34,992  

Operating digital assets

71  

 

 

 

 

 

71  

Inventory

711,269  

 

 

 

 

 

711,269  

Prepaid expense

91,378  

 

 

 

 

 

91,378  

Total current assets

3,007,651  

 

 

 

 

 

3,257,651  

Other Assets

 

 

 

 

 

 

 

Intangible assets

170,307  

 

2,025,000 

 

 

 

2,195,307  

Deposits

4,400  

 

 

 

 

 

4,400  

Right -of-use asset

21,870  

 

 

 

 

 

21,870  

Total other assets

196,577  

 

 

 

 

 

2,221,577  

 

 

 

 

 

 

 

 

Total Assets

$3,204,228  

 

$2,025,000 

 

$250,000 

 

$5,479,228  

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

Accounts payable

$38,653  

 

 

 

 

 

$38,653  

Accrued expenses

26,201  

 

 

 

 

 

26,201  

Deferred research funding

 

 

 

 

250,000 

 

250,000  

Deferred revenue

1,522  

 

 

 

 

 

1,522  

Related party advances

8,803  

 

 

 

 

 

8,803  

Insurance loan

25,935  

 

 

 

 

 

25,935  

Note payable - related party

180,402  

 

 

 

 

 

180,402  

Total current liabilities

$281,516  

 

 

 

$250,000 

 

$531,515  

 

 

 

 

 

 

 

 

STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

 

Preferred stock: $0.0001 par value, 5,000,000 shares authorized;

-

 

 

 

 

 

-  

Series A Convertible Preferred Stock, 1,000,000 designated,
140,000 shares issued and outstanding at September 30, 2026

14  

 

 

 

 

 

14  

Common stock: $0.0001 par value, 250,000,000 shares authorized;
12,477,217 shares issued and outstanding at
September 30, 2026 pro forma adjusted

1,203  

 

45 

 

 

 

1,248  

Additional paid-in capital, pro forma as adjusted

3,185,373  

 

2,024,955 

 

 

 

5,210,328  

Accumulated earnings (deficit)

(263,878) 

 

 

 

 

 

(263,878) 

Total stockholders' equity (deficit)

2,922,712  

 

2,025,000 

 

 

 

4,947,712  

Total Liabilities and Stockholders' Equity (Deficit)

$3,204,228  

 

$2,025,000 

 

$250,000 

 

$5,479,228  

 

Board Expansion in Connection with Planned Uplisting

 

Subsequent to September 30, 2026, BioScience Health Innovations Corp. (the “Company”) announced that two independent board member candidates, Mark Woodruff and Mark Thomas, have agreed to join the Company’s Board of Directors, with their appointments expected to become effective in connection with the Company's planned application to uplist to a senior U.S. securities exchange.

 

Mark Woodruff brings more than 30 years of experience in finance, investment management, and wealth advisory services. He earned a Bachelor of Science in Finance from the University of Utah in 1992 and an MBA from Brigham Young University in 1996. His professional background includes Fidelity Investments (1993–2000), Goldman Sachs (2000–2016), Alta Capital (2016–2022), and Physician Wealth Advisors (2022–present).

 

Mark Thomas brings more than 40 years of experience in business, sales, service, and construction, including 16 years in executive leadership. His background includes managing multimillion-dollar projects, overseeing budgets, revenue forecasting, and directing business operations. He also has an extensive history of community involvement throughout Utah.

The Company believes these prospective appointments will strengthen its corporate governance, financial oversight, and strategic leadership as it pursues a senior exchange listing. The planned appointments and potential uplisting remain subject to applicable corporate approvals, listing requirements, and other relevant conditions.

 

Engagement of Uplisting Advisor

 

Subsequent to the quarter ended September 30, 2026, BioScience Health Innovations Corp. (the “Company”) engaged Donohoe Advisory Associates LLC (www.donohoeadvisory.com) to provide strategic advisory services in connection with the Company’s pursuit of an uplisting of its common stock to a senior U.S. securities exchange. The engagement reflects the Company’s ongoing efforts to strengthen its capital markets position, enhance shareholder visibility, and pursue broader institutional investor access. There can be no assurance that the Company will satisfy applicable listing requirements or successfully complete an uplisting.


13


 

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Regarding Forward Looking Statements

 

This Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our discussions and the anticipated terms of a potential reverse merger pursuant to which we would acquire an operating business, our business plan and our liquidity needs. All statements other than statements of historical facts contained in this Report, including statements regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

 

The results anticipated by any or all of these forward-looking statements might not occur. Important factors, uncertainties and risks that may cause actual results to differ materially from these forward-looking statements include those described elsewhere in this Report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under “Item 1A. – Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

 

Recent Developments

 

Corporate Name Change

 

On February 21, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Formation with the Secretary of State of Nevada to change the Company’s corporate name to “BioScience Health Innovations Inc.”, with an effective date of February 21, 2025. The name change was approved by the Company’s Board of Directors on February 21, 2025.

 

Overview

 

As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting includes: Dementia and Alzheimer’s disease, ADHD and ADD, Long Covid, General Energy, Traumatic Brain Injury, Mild Cognitive Decline, GLP-1 Weight Loss, Sleep Improvement, Epilepsy and Seizure Reduction and Nasal Health and Allergy.

 

A trend that we believe is very beneficial and encouraging is the recent growing interest in mitochondria health and the role that mitochondria dysfunction plays in mental health and physical health issues. Methylene Blue and specialty natural options has emerged as valuable foundational health options on these fronts. We believe we are very well positioned and with adequate capital infusion we will be able to capitalize on multiple market opportunities.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Management’s discussion and analysis and results of operations are based upon our accompanying financial statements for the nine months ended September 30, 2026, which have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Note 3. Summary of Significant Accounting Policies, to the financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, describes the significant accounting policies and methods used in the preparation of the Company’s financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. These estimates are the basis for our judgments about the carrying values of assets and liabilities, which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under different assumptions or conditions.

 

Results Of Operations

 

THREE MONTHS ENDED SEPTEMBER 30, 2026 COMPARED TO SEPTEMBER 30, 2025

 

Our net loss for the three months ended September 30, 2026 was $149,225 compared to a net loss of $8,782 during the three months ended September 30, 2025. The Company has generated revenue of $970,071 and $1,131,427 during the three months ended September 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company also had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Expenses incurred were operating expenses of $785,824 during the three months ended September 30, 2026, compared to $707,013 during the three months ended September 30, 2025. Expenses increased as a result of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.


14


 

Table of Contents

 

NINE MONTHS ENDED SEPTEMBER 30, 2026 COMPARED TO SEPTEMBER 30, 2025

 

Our net loss for the nine months ended September 30, 2026 was $564,885, compared to a net income $875,720 during the nine months ended September 30, 2025. The Company has generated revenue of $2,757,381 and $4,115,960 during the nine months ended September 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Operating expenses were $2,378,692 during the nine months ended September 30, 2026, compared to $1,793,134 during the nine months ended September 30, 2025. Expenses increased because of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of September 30, 2026, our total assets were $3,204,228, consisting of cash, accounts receivable, income tax receivable, digital assets, inventory, prepaid expenses, right-of-use assets, deposits, and intangible assets. The Company’s net working capital was $2,726,135 and management believes that its cash balance of $1,691,858 as of September 30, 2026 is sufficient to meet its obligations over the next year.

 

Cash Flows from Operating Activities

 

We have generated negative cash flows from operating activities. For the nine months ended September 30, 2026, net cash flows used in operating activities was $1,244,807, consisting of our net loss of $564,885 plus changes in operating activities of $679,922. For the nine months ended September 30, 2025, net cash flows providing in operating activities was $272,874, consisting of our net income of $875,720 offset by changes in operating activities of $602,846.

 

Cash Flows from Investing Activities

 

For the nine months ended September 30, 2026, we had net cash used in investing activities of $87,420 in connection with the purchase of intangible assets. For the nine months ended September 30, 2025, we had net cash used in investing activities of $46,064 in connection with the purchase of intangible assets.

 

Cash Flows from Financing Activities

 

For the nine months ended September 30, 2026, net cash flows provided by financing activities was $2,362,160, consisting of $756,923 in advances from related parties, advances from insurance loan of $42,663 and $2,010,267 of cash acquired for selling common stock, offset by repayments of related party advances of $150,000 and repayment of a related party note payable of $280,000 and repayments to insurance loan of $17,693. For the nine months ended September 30, 2025, net cash flows provided by financing activities was $250,096, consisting of advances from related parties of $2,422,096 offset by repayments to related parties of $2,172,000.

 

PLAN OF OPERATION AND FUNDING

 

The BioScience Health Innovations’ management team plans to focus on gaining traction for its mental health and general wellness products. Best 365 Labs, Inc has filed for a provisional patent on its mental wellness, natural products which is an additional reason we plan to focus and grow this sector of the products. With the Global Mental Health Marketplace currently valued at $383.31 billion annually and with 41 million people holding a prescription for Adderall that the market conditions are idea for us to offer our natural substitute product options (which are also unique).

 

As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in these potential marketplaces, through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting include:


15


 

Table of Contents

 

ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

1. Executive Overview — Building a Cellular-Wellness and Delivery-Technology Platform

 

BioScience Health Innovations, Inc. (the “Company,” “BHIC,” “we” or “our”), through Best 365 Labs, is pursuing a business strategy built around differentiated consumer-health products and the potential commercialization of proprietary delivery technology. Management believes that MODS Max, a patent-pending stabilized aqueous mineral-oxide formulation system, represents a principal long-term strategic opportunity. The objective is to build both a commercially productive product portfolio and, subject to independent validation and market acceptance, a delivery platform that unrelated businesses may pay to incorporate or license.

 

Our “Ground Zero” cellular-wellness approach emphasizes products positioned around mitochondrial and foundational wellness. MODS Max is intended to serve as common formulation infrastructure across multiple compatible products, rather than a separate active ingredient. Management believes this model may provide additional sources of revenue beyond sales of individual products; those sources have not yet been established.

 

During 2026 management has devoted significant leadership attention and operating resources to supply-chain qualification, formulation and intellectual-property development, technical documentation, accounting infrastructure, and preparation for prospective strategic partners. These efforts have competed with time and resources available to near-term sales initiatives. Management considers this allocation a deliberate strategic priority, including in connection with its objective of improving readiness for a potential senior-exchange uplisting.

 

2. MODS Max — Our Core Strategic Technology

 

2.1 Technology and proposed mechanism

 

MODS Max is described in Company technical materials as a proprietary, stabilized aqueous mineral-oxide system intended for incorporation into selected sublingual, nasal and other formulations. Its value proposition relates to proprietary composition, processing, stabilization, formulation experience and possible effects on delivery of compatible active ingredients. Certain elements are the subject of pending patent applications; other details are maintained as confidential know-how. Patent applications do not assure patent issuance, breadth or enforceability.

 

The Company’s proposed technical hypothesis involves redox-associated interactions at biological interfaces and possible effects on epithelial transport. These mechanisms have not been established for MODS Max in controlled, independently reproducible human studies across the contemplated routes. No general absorption multiplier is asserted. Commercial use or formulation stability does not independently establish enhanced absorption.

 

2.2 Commercial deployment and operational validation

 

Company materials describe the incorporation of MODS Max into more than 30 formulations across cellular wellness, mitochondrial support, sleep, recovery and hormone-related product categories. Commercial liquid and nasal applications provide practical experience in formulation, manufacturing, product-specific stability, quality testing, distribution and customer adoption. Selected formulations have internal real-time stability observations extending beyond 12 months, subject to the tested products and conditions.

 

Management also considers its owned product lines and co-branded formulations important commercial reference applications for prospective third-party partners. Such experience constitutes operational and commercial deployment, not proof that MODS Max independently improves bioavailability or clinical outcomes. Independent route- and payload-specific studies remain necessary.

 

2.3 Routes and formats

 

Sublingual liquids

Commercial experience; selected compact-volume formulations.

Nasal sprays

Commercial formulations; nasal compatibility, safety and pharmacokinetic performance require product-specific evaluation.

Topical and scalp

Development opportunity; clinical performance and skin transport not independently validated.

Swallowed oral

Development opportunity; sublingual observations do not establish GI delivery.

Liquid-filled capsules

Prospective formulation opportunity, contingent on stability and compatibility.

Dry powders and stick packs

Prospective format and licensing opportunity; drying feasibility and performance unproven.


16


 

Table of Contents

 

3. Intellectual Property and Competitive Position

 

The Company intends to differentiate through a combination of pending patent applications, proprietary formulation and stabilization methods, confidential technical know-how, manufacturing experience and, ultimately, measurable delivery performance. MODS Max competes for commercial relevance with established liposomal, lipid-based, nasal absorption-enhancement and oral-delivery technologies. These technologies illustrate the quality of evidence that sophisticated partners may require; they do not validate MODS Max by analogy. Freedom-to-operate analyses, patent prosecution and commercial claim scope remain important development considerations.

 

4. Scientific and Regulatory Validation

 

Management views a sequenced validation program as important to reducing technical and commercial uncertainty: (i) independent chemical characterization of the input and finished formulations, including relevant reactive constituents and degradation products; (ii) ingredient- and route-specific safety and regulatory assessments; (iii) controlled matched-formulation transport studies; and (iv) pharmacokinetic and other human research where justified and authorized. No performance study should be interpreted as establishing safety or lawful use for other products or routes.

 

A 2026 retrospective case series involving 15 men using a sublingual enclomiphene formulation incorporating a mineral-oxide system reported an increase in mean testosterone from approximately 347 ng/dL to 805 ng/dL at 60 days and no serious adverse events in the reported group. The study was small, uncontrolled and did not include an enclomiphene-only comparison. It therefore cannot isolate the independent contribution of MODS Max and does not establish the platform’s comparative delivery benefit or comprehensive safety.

 

The Company is evaluating nasal and peptide-related possibilities, but has not demonstrated injection-equivalent exposure, direct nose-to-brain delivery, or route-wide peptide bioavailability. Product-specific toxicology, analytical methods and applicable regulatory requirements are material prerequisites to any broader pharmaceutical applications.

 

5. Markets and Product Applications

 

Current and prospective applications include cellular and NAD-related wellness, mitochondrial-support products, hormone-related formulations, metabolic and GLP-1-adjacent wellness, menopause-related products, selected peptide-related research, skincare and hair/scalp products. Market participation is subject to distinct competitive and regulatory conditions. References to large adjacent pharmaceutical or consumer markets do not establish the Company’s addressable share or the economic value of MODS Max. In particular, potential benefits in weight loss, hormone therapy or peptide administration require product-specific substantiation and appropriate legal pathways.

 

The Company’s portfolio strategy emphasizes using current formulations to generate product revenue and provide practical development experience while identifying applications in which future technical validation and partner demand may support a separate licensing opportunity.

 

6. Commercial Strategy — From Owned Products to External Adoption

 

The current primary economic model is the sale of Company-owned products through direct-to-consumer, wholesale, clinical and other distribution relationships, together with selected co-branded applications. These products may support cash generation, customer learning, manufacturing repeatability and potential partner references.

 

The longer-term model under evaluation is adoption by unrelated commercial partners. Subject to demonstrated technical usefulness and acceptable commercial terms, this could include technology-access fees, formulation services, input or finished-product supply, field-specific licenses, development milestones and royalties. Licensing is not automatically recurring or high-margin; economics depend on the rights granted, technical support, contractual obligations, partner demand and ongoing costs. No completed arm’s-length third-party MODS Max license has been established in the materials supporting this draft.

 

Management believes that a paid, independently negotiated third-party technology agreement would represent an important transition: evidence that a business outside BHIC values MODS Max sufficiently to commit commercial resources. The Company’s long-term objective is not simply to sell more products incorporating MODS Max, but to create opportunities to participate economically in products developed, financed and sold by third parties.

 

7. Valuation Perspective — One Platform, Multiple Potential Revenue Models

 

Management considers MODS Max a potential multi-application technology asset rather than solely an ingredient supporting individual consumer products. The Company does not believe its value can be established by adding together market-size estimates for all prospective categories, and does not equate prospective opportunities with realized financial value.

 

A disciplined evaluation would consider incremental operating contribution from existing technology-enabled products, strength of intellectual-property rights, reproducible technical evidence, safety and regulatory feasibility, development costs, partner demand, observed licensing terms, and risk-adjusted future cash flows. Any enterprise valuation must avoid double counting product operating cash flows and related technology benefits.


17


 

Table of Contents

 

The Company has not obtained an independent appraisal of MODS Max. Capitalized patent costs of $109,845 shown in the working financial notes reflect accounting cost rather than an estimate of the platform’s fair market value; this amount and the applicable reporting period must be reconciled before filing. The Company does not assert a current technology value, valuation multiple or stock-price target in this MD&A.

 

7.1 Potential value-inflection stages

 

Current product commercialization

Evidence of formulation, manufacturing and distribution feasibility, but not controlled comparative delivery advantage.

Independent chemistry, safety and performance studies

May reduce technical and regulatory uncertainty for defined formulations.

Arm’s-length outside technology agreement

Could provide observable willingness-to-pay and contract-based economic evidence.

Repeated licensing and contractual royalties

Could establish scalable, recurring economics if commercially successful.

Validated solid formats and pharmaceutical development

Potential longer-term opportunity requiring additional research, capital and regulatory work.

 

8. Priority Development Milestones

 

Management’s proposed milestones are: independent chemical characterization and route-specific risk assessment; matched active-with/without-MODS Max performance testing; selected nasal and peptide investigations where legally and scientifically appropriate; capsule and dry-format feasibility; pursuit of an initial arm’s-length external licensing or funded-development arrangement; and, only if warranted, exploration of pharmaceutical development partnerships. The sequence, timing and capital requirements will depend on findings, management decisions and available resources. No milestone is assured.

 

9. Clinical, Technical and Commercial Relationships

 

Company advisory and commercial relationships have supported product formulation, education and distribution initiatives. Management intends to use qualified independent laboratories and appropriate scientific advisors to build an evidence base suitable for external evaluation. Medical relationships and publications do not substitute for controlled comparative studies. The Company may pursue technology and co-brand relationships subject to verified contractual status, scope, financial terms and regulatory requirements.

 

10. Operating Infrastructure and Strategic Resource Allocation

 

The Company has described a deliberate operational transition involving separation from a prior affiliated supply arrangement, supplier qualification, product-portfolio repositioning, development of quality systems, and a NetSuite accounting and inventory upgrade. Management believes these activities are intended to improve scalability, margin visibility, inventory accuracy and public-company readiness. Their financial benefits remain subject to execution and measurable results.

 

Preparatory activities concerning MODS Max—including intellectual-property work, development of technical documentation, identification of analytical needs and potential partner readiness—have required meaningful management time, energy and operating resources. Management has prioritized this work because it believes a successfully validated and adopted platform could offer a broader set of commercial revenue models than individual branded products alone.

 

11. Results of Operations — Reconciliation Required

 

Three Months Ended September 30, 2026 versus 2025

 

Our net loss for the three months ended September 30, 2026 was $149,225 compared to a net loss of $8,782 during the three months ended September 30, 2025. The Company has generated revenue of $970,071 and $1,131,427 during the three months ended September 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company also had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Expenses incurred were operating expenses of $785,824 during the three months ended September 30, 2026, compared to $707,013 during the three months ended September 30, 2025. Expenses increased as a result of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.


18


 

Table of Contents

 

Nine Months Ended September 30, 2026 versus 2025

 

Our net loss for the nine months ended September 30, 2026 was $564,885, compared to a net income $875,720 during the nine months ended September 30, 2025. The Company has generated revenue of $2,757,381 and $4,115,960 during the nine months ended September 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Operating expenses were $2,378,692 during the nine months ended September 30, 2026, compared to $1,793,134 during the nine months ended September 30, 2025. Expenses increased because of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.

 

Management acknowledges that the reported year-over-year revenue decline, once verified, is a material measure of current-period operating performance. Relevant causes include changes in sales and distribution strategies, supplier and operating transitions, the time and resources devoted to technology and infrastructure preparation, and the timing of anticipated distribution opportunities. The Company should quantify each cause to the extent material and supported by its records.

 

Management further reports that several distribution opportunities originally expected to contribute in 2026 have been delayed, with certain anticipated launches or orders now targeted for 2027. The final filing should distinguish signed arrangements from discussions or nonbinding opportunities and explain material terms and any reasonably known effect on results. Revenue in 2027 is not assured.

 

12. Liquidity and Capital Resources

 

As of September 30, 2026, our total assets were $3,204,228, consisting of cash, accounts receivable, income tax receivable, digital assets, inventory, prepaid expenses, right-of-use assets, deposits, and intangible assets. The Company’s net working capital was $2,726,135 and management believes that its cash balance of $1,691,858 as of September 30, 2026 is sufficient to meet its obligations over the next year.

 

Cash Flows from Operating Activities

 

We have generated negative cash flows from operating activities. For the nine months ended September 30, 2026, net cash flows used in operating activities was $1,244,807, consisting of our net loss of $564,885 plus changes in operating activities of $679,922. For the nine months ended September 30, 2025, net cash flows providing in operating activities was $272,874, consisting of our net income of $875,720 offset by changes in operating activities of $602,846.

 

Cash Flows from Investing Activities

 

For the nine months ended September 30, 2026, we had net cash used in investing activities of $87,420 in connection with the purchase of intangible assets. For the nine months ended September 30, 2025, we had net cash used in investing activities of $46,064 in connection with the purchase of intangible assets.

 

Cash Flows from Financing Activities

 

For the nine months ended September 30, 2026, net cash flows provided by financing activities was $2,362,160, consisting of $756,923 in advances from related parties, advances from insurance loan of $42,663 and $2,010,267 of cash acquired for selling common stock, offset by repayments of related party advances of $150,000 and repayment of a related party note payable of $280,000 and repayments to insurance loan of $17,693. For the nine months ended September 30, 2025, net cash flows provided by financing activities was $250,096, consisting of advances from related parties of $2,422,096 offset by repayments to related parties of $2,172,000.

 

Technology development may require additional spending on analytical testing, independent toxicology, regulatory review, clinical studies, patent prosecution and partner qualification. The Company intends to prioritize development investments based on available financing, findings and commercial relevance. Financing and any associated dilution or debt obligations must be evaluated in connection with the Company’s broader operating needs.

 

13. Capital Markets and Senior-Exchange Preparation

 

Management has undertaken initiatives intended to strengthen accounting and inventory systems, governance, shareholder access and potential senior-exchange readiness. The Company has described Regulation A financing activity and engagement of advisors concerning an uplisting. Completion of an exchange listing is subject to applicable requirements and does not assure improved liquidity, a higher trading price or funding availability.

 

The working filing also describes material weaknesses in disclosure controls and financial reporting controls. Management should align any discussion of operational and institutional readiness with the status of its control-remediation plan and the Company’s actual financial-reporting capability.


19


 

Table of Contents

 

14. Outlook — Strategic Transformation and Long-Term Shareholder-Value Creation

 

2026: Building the Foundation for Long-Term Growth

 

Management views 2026 as an important period of strategic transformation. Although reported revenue has declined year over year, subject to reconciliation of the finalized financial statements, management believes current-period financial performance does not fully describe the Company’s efforts to expand its technological and commercial capabilities. During the period, management deliberately devoted substantial leadership attention and resources to MODS Max, including formulation work, intellectual-property development, technical documentation, supplier qualification, and preparation for potential independent evaluation and strategic partnerships.

 

These initiatives have competed with resources that otherwise could have been deployed toward near-term sales and distribution activities. Management views this priority as consistent with its objective of creating a business with both ongoing product revenue and potential technology-related revenue streams. The Company cannot establish that this allocation will produce an offsetting financial benefit.

 

Owned Products and Co-Branded Applications as the First Commercial Foundation

 

The Company’s own product lines and co-branded applications are important to the MODS Max development story. They demonstrate practical incorporation of the platform into multiple commercial formulations and provide operational evidence regarding product development, manufacturing, selected product stability, distribution and consumer adoption. Management views this experience as the first stage of commercial deployment and as potential reference applications for prospective partners.

 

This experience should not be confused with independent demonstration of improved absorption or clinical efficacy attributable to MODS Max. Management intends to distinguish operational commercialization from subsequent technical validation and independent economic adoption.

 

Deliberate Investment in Technology and Institutional Readiness

 

Management believes preparation of MODS Max for further scientific evaluation and partner review is strategically important. The work has taken significant time, effort and operating resources, in parallel with investments intended to strengthen accounting systems, supplier relationships and public-company infrastructure. Management considers these actions relevant to the Company’s potential senior-exchange objectives, while recognizing that uplisting depends on separate exchange, market, governance and regulatory conditions and is not assured.

 

Distribution Opportunities Moving Into 2027

 

Several distribution initiatives that management previously anticipated would generate revenue in 2026 have been delayed, with certain expected commercial launches or orders now anticipated in 2027. Management continues to pursue these opportunities, but future launches, orders and revenue depend on counterparty decisions, executed agreements, product readiness and other conditions. There can be no assurance that the anticipated business will commence in 2027 or generate the revenue originally contemplated.

 

These timing changes provide context for operating results, but do not eliminate the importance of addressing the current revenue decline or achieving sustainable profitability and positive cash flow.

 

Three Stages of MODS Max Value Development

 

Management evaluates progress through three distinct stages: (1) commercial deployment in owned and co-branded products; (2) independent technical validation, including chemical, safety and controlled comparative delivery evidence; and (3) independent economic validation through arm’s-length paying third-party relationships. The Company has experience in the first stage, is developing a program for the second and has not established the third as a recurring revenue model.

 

Our Long-Term Shareholder-Value Perspective

 

Management believes the most important potential opportunity is not simply to sell additional products powered by MODS Max. It is to establish MODS Max as an independently validated, commercially adopted delivery technology that unrelated businesses are willing to pay to access, incorporate and license.

 

If achieved, this transition could allow BHIC to participate in selected products developed, financed, manufactured and sold by other businesses and could provide additional contractual revenue models beyond sales of Company-owned brands. Management believes its 2026 development activities have expanded the potential pathways available for pursuing that objective. This does not establish an increase in fair market value, and the Company has not independently quantified an increase in MODS Max’s value or demonstrated that future opportunities will generate incremental cash flow.

 

The long-term financial impact remains contingent on technical results, legal and regulatory feasibility, effective intellectual-property protection, partner demand, financing, and operating execution. Management remains focused on improving underlying product performance and advancing the platform through objective validation and commercial milestones.


20


 

Table of Contents

 

15. Forward-Looking Statements and Material Uncertainties

 

Statements concerning MODS Max performance, future products and routes, research, distribution launches, strategic partnerships, licensing, future results, platform value, financing and an exchange uplisting are forward-looking and involve uncertainties. Actual outcomes may differ materially. Commercial use, patent-pending status, preliminary human observations and internally prepared strategic analyses do not establish independently verified delivery performance, regulatory authorization, an appraisal of the technology or any future value of the Company’s common stock. The Company’s applicable risk disclosures and finalized financial statements should be considered with this discussion.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

As of September 30, 2026 (the “Evaluation Date”), the Company’s management evaluated, with participation of its principal executive officer, the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on that evaluation, the Company’s principal executive officer concluded that the Company’s disclosure controls and procedures were ineffective as of September 30, 2026.

 

Management assessed the effectiveness of its internal control over financial reporting as of the Evaluation Date based on criteria for effective internal control over financial reporting described in Internal Control—Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. The material weaknesses identified during management’s assessment were (i) a lack of sufficient internal accounting resources; (ii) a lack of segregation of duties to ensure adequate review of financial statement preparation, (iii) lack of an independent board of directors or audit committee, and (iv) lack of written documentation of our internal control policies and procedures. In light of these material weaknesses, management has concluded that we did not maintain effective internal control over financial reporting at the Evaluation Date. We plan to rectify these weaknesses by establishing written policies and procedures for our internal control of financial reporting and hiring additional accounting personnel at such time as we raise sufficient capital to do so. There were no changes in controls during the quarter ended September 30, 2026.


21


 

Table of Contents

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

 

Item 1A. Cybersecurity

 

To date, the Company has not identified any cybersecurity incidents which have materially affected, or are reasonably likely to materially affect, the Company’s business strategy, results of operations or financial condition.  The Company has not implemented any specific policies with respect to monitoring and managing cybersecurity threats. Moreover, the Company is aware of the evolution of cybersecurity risks and is taking proactive steps by keeping up to date our information systems and educating our personnel about these risks.

 

The Company recognizes the importance of developing, implementing, and maintaining cybersecurity measures to safeguard its information systems and protect the confidentiality, integrity, and availability of the data. The Company will be looking to adopt cybersecurity processes, technologies and controls to aid in its efforts to assess, prevent, identify and manage such risks.

 

Item 2. Unregistered Sales Of Equity Securities and Use Of Proceeds

 

During the nine months ended September 30, 2026, the Company issued 1,048,159 shares in common stock for cash proceeds of $2,010,267.

 

Item 3. Defaults Upon Senior Securities

 

Not applicable.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

Not applicable.


22


 

Table of Contents

 

Item 6. Exhibits

 

Exhibit #

 

Exhibit Description

 

Incorporated By Reference

 

Filed or
Furnished Herewith

 

 

 

 

Form

 

Date

 

Number

 

 

3.1(a)

 

Articles of Incorporation

 

S-1

 

11/4/2019

 

3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

3.1(b)

 

Amendment to Articles of Incorporation

 

10-K

 

11/26/2021

 

3.1B

 

 

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Bylaws

 

S-1

 

11/4/2019

 

3.2

 

 

 

 

 

 

 

 

 

 

 

 

 

10.1

 

Stock purchase agreement dated August 29, 2022*

 

10-Q

 

08/11/2023

 

10.1

 

 

 

 

 

 

 

 

 

 

 

 

 

10.2

 

Stock purchase Agreement dated October 19, 2022*

 

10-Q

 

08/11/2023

 

10.2

 

 

 

 

 

 

 

 

 

 

 

 

 

10.3

 

Stock purchase Agreement dated December 20, 2022

 

10-Q

 

08/11/2023

 

10.3

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification of Principal Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)

 

 

 

 

 

 

 

Filed

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Certification of Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)

 

 

 

 

 

 

 

Filed

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Certification of Principal Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002

 

 

 

 

 

 

 

Furnished**

 

 

 

 

 

 

 

 

 

 

 

32.2

 

Certification of Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002

 

 

 

 

 

 

 

Furnished**

 

 

 

 

 

 

 

 

 

 

 

101

 

Inline Interactive data files pursuant to Rule 405 of Regulation S-T

 

 

 

 

 

 

 

Filed

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

 

 

 

*

Certain schedules, appendices and exhibits have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule, appendix and/or exhibit will be furnished supplementally to the Staff of the Securities and Exchange Commission upon request.

 

 

**

This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.


23


 

Table of Contents

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BioScience Health Innovations Inc.

 

 

 

Dated: November 13, 2026

By:

/s/ Darren Lopez

 

 

Darren Lopez

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ Darren Lopez

 

Principal Executive Officer and Director

 

November 13, 2026

Darren Lopez

 

 

 

 


24

Keep reading